Ascendis Pharma A/S
ASND
247 hedge funds and large institutions have $10.9B invested in Ascendis Pharma A/S in 2025 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 82 increasing their positions, 88 reducing their positions, and 40 closing their positions.
210% more call options, than puts
Call options by funds: $39.2M | Put options by funds: $12.6M
14% more funds holding in top 10
Funds holding in top 10: 14 → 16 (+2)
10% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 40
7% more capital invested
Capital invested by funds: $10.1B → $10.9B (+$708M)
1% more funds holding
Funds holding: 244 → 247 (+3)
7% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 88
4.51% less ownership
Funds ownership: 107.4% → 102.88% (-4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$157M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$86.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$53.8M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$50.9M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$269M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$88.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$87.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$62M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$43.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
276
Bridgefront Capital
Austin,
Texas
| – | -$267K | -1,714 | Closed |
|
277
Northern Trust
Chicago,
Illinois
| – | -$248K | -1,592 | Closed |
|
|
JF
278
Jump Financial
Chicago,
Illinois
| – | -$228K | -1,461 | Closed |
|
279
Acadian Asset Management
Boston,
Massachusetts
| – | -$64K | -411 | Closed |
|
|
QCG
280
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$58K | -372 | Closed |
|
|
SAM
281
Smartleaf Asset Management
Boston,
Massachusetts
| – | -$9.74K | -63 | Closed |
|
|
QC
282
Quent Capital
New York
| – | -$5.92K | -38 | Closed |
|
|
PTC
283
Private Trust Company
Cleveland,
Ohio
| – | -$4.05K | -26 | Closed |
|
|
CCM
284
Coldstream Capital Management
Bellevue,
Washington
| – | -$2.81K | -18 | Closed |
|
|
SW
285
SVB Wealth
Boston,
Massachusetts
| – | -$2.81K | -18 | Closed |
|
|
HCP
286
Hexagon Capital Partners
Rogers,
Arkansas
| – | -$2.34K | -15 | Closed |
|
287
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$2.02K | -13 | Closed |
|
|
LFG
288
Larson Financial Group
St Louis,
Missouri
| – | -$1.4K | -9 | Closed |
|
ASND Hedge Fund Activity: Q2 2025 in Review
247 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2025, worth a combined $10.9B — up 7% from $10.1B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ASND positions and 40 closed out — a net gain of 4 holders — while 82 added to existing stakes and 88 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $157M. The largest seller was Morgan Stanley, cutting an estimated $269M.
- 247 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2025, up from 244 in Q1 2025.
- Funds reported $10.9B of Ascendis Pharma A/S stock for Q2 2025, up 7% quarter-over-quarter.
- 44 funds opened new Ascendis Pharma A/S positions in Q2 2025 and 40 closed out, a net change of +4 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2025 was Perceptive Advisors, an estimated $157M added.
- The largest Ascendis Pharma A/S seller in Q2 2025 was Morgan Stanley, an estimated $269M sold.
Based on aggregated 13F filings for Q2 2025.